Covid-19 VoC mAb

Covid-19 VoC mAb is a monoclonal antibody currently in preclinical development by Panacea Biotec in collaboration with the Translational Health Science and Technology Institute (THSTI). The therapeutic candidate is specifically designed to neutralize SARS-CoV-2 and its emerging variants of concern (VoC). As a monoclonal antibody, its primary mechanism of action involves binding to specific viral antigens—typically the spike protein—to block viral entry into host cells and prevent infection. This candidate is part of Panacea Biotec's specialized pipeline focused on infectious diseases, aiming to provide a targeted treatment or prophylactic option against the evolving landscape of COVID-19 variants.

Other names

SARS-CoV-2 VoC monoclonal antibodySARS-CoV2 VoC monoclonal antibodySARS-CoV 2 VoC monoclonal antibodyCOVID-19 variant of concern monoclonal antibodyCOVID19 variant of concern monoclonal antibodyCOVID 19 variant of concern monoclonal antibodyCOVID-19 variant of concern monoclonal antibody-Panacea Biotec-SARS-CoV-2 and variants of concern-monoclonal antibody-COVID-19COVID19 variant of concern monoclonal antibody-Panacea Biotec-SARS-CoV-2 and variants of concern-monoclonal antibody-COVID-19COVID 19 variant of concern monoclonal antibody-Panacea Biotec-SARS-CoV-2 and variants of concern-monoclonal antibody-COVID-19